Manufacture of experimental antineoplastic drug Pixantrone will begin at NerPharMa DS' facility in Nerviano, Italy, after the site was given approval by the Italian Medicines Agency.
The drug, developed by Cell Therapeutics (CTI), is an analogue of mitoxantrone with less toxic effects on cardiac tissue.
It acts as a topoisomerase II poison and intercalating agent.
CTI is in the process of preparing a marketing authorisation application in the EU for Pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma.
NerPharMa DS is a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences.